OSE Immunotherapeutics presents promising data on the mRNA platform at the FOCIS congress

On June 20, 2024, the company OSE Immunotherapeutics unveiled encouraging preclinical results on its therapeutic mRNA platform at the FOCIS congress in San Francisco. Data show that mRNA therapeutic targeting Interleukin-35 (IL-35), used via lipid nanoparticles, effectively reduces hepatic autoimmune inflammation.

IL-35 is an immunosuppressive cytokine modulating several immune cells to limit inflammation. Preclinical studies have demonstrated that it plays a crucial role in the control of autoimmune and inflammatory diseases, including autoimmune hepatitis.

Aurore Morello, Director of R&D at OSE Immunotherapeutics, expressed satisfaction with the initial results, highlighting the potential of this new approach to address an important medical need in autoimmune and inflammatory diseases.